neuroClues Secures €10M Series A to Bring Advanced Eye-Tracking Diagnostic to Neurologists
neuroClues, a French-Belgian medtech company developing an AI-powered eye-tracking device for early neurological disorder diagnosis, has closed a €10 million Series A round. This follows the company receiving CE certification for its Class IIa medical device in January 2025, allowing its use across Europe.
The startup’s innovative device captures up to 800 infrared images per eye per second through a portable, connected headset as users visually track a moving target on screen. Utilizing AI models, it extracts oculomotor biomarkers within minutes, indicating neurological conditions like Parkinson’s disease, Alzheimer’s, and multiple sclerosis – sometimes years before clinical symptoms appear.
Founded in 2020 by Antoine Pouppez, Pierre Daye, and Pierre Pouget (the latter two neuroscience researchers), neuroClues builds on a long history of eye-tracking research for neurological diagnosis dating back to 1905. Despite decades of evidence, traditional hardware limitations have hindered its clinical adoption.
The company’s device addresses this gap, targeting the 2.3 million physicians worldwide who currently assess brain health through conventional methods. With the growing Parkinson’s diagnosis challenge – projected to reach 13 million globally by 2040 – neuroClues’ technology could significantly impact early detection and treatment.
The neuroClues device has been integrated into the Iceberg cohort study at Paris Brain Institute within La Salpêtrière Hospital, led by Professors Marie Vidailhet and Stéphane Lehéricy, focusing on early Parkinson’s detection biomarkers.